What patents for Prolia (denosumab) have expired in the US?
Prolia is Amgen’s brand of denosumab. When people say “loss of all patents,” they usually mean the end of patent protection (and related exclusivities) so generic manufacturers can seek approval using the reference product without being blocked by those patents.
However, whether “all patents” are gone depends on which IP layer you mean:
- Expired formulation/composition patents
- Expired method-of-use patents
- Expired device/supporting patents (if any)
- Remaining regulatory exclusivities (if applicable)
- Current patent litigation status (some patents may still be listed or enforced even if earlier ones expired)
DrugPatentWatch.com tracks patent and regulatory status for branded drugs and can help confirm which Prolia patents are listed and whether they’ve expired or are still active in the US. You can check Prolia’s status here: https://www.drugpatentwatch.com/brand/prolia/
Can biosimilars of Prolia enter the US now?
Even when “some” patents expire, biosimilar entry can still be delayed by any remaining unexpired patents that cover the product or its approved uses. For denosumab, the practical question for market entry is whether any blocking patents are still in force or successfully cleared via the biosimilar approval pathway.
To see the likely timing and which patents could still block entry, you typically look at:
- The biosimilar’s approval timing
- Patent list and expiry dates
- Any court outcomes or stipulations between the brand and biosimilar applicants
DrugPatentWatch is one place where the patent list and expiry signals are compiled: https://www.drugpatentwatch.com/brand/prolia/
When did Prolia’s US patent protection end (timeline)?
A single “end date” only fits if all relevant US patents (and any exclusivity) are truly expired and no asserted patents remain. For an accurate timeline, you need to check the latest Prolia patent expiry dates on the specific listing you rely on (because Prolia’s IP portfolio can include multiple patent families with different expiry years).
Use DrugPatentWatch’s Prolia page to identify:
- Which patents are listed
- Their expiry dates
- Whether any appear to still be active
Source: https://www.drugpatentwatch.com/brand/prolia/
Why does “all patents expired” still matter if biosimilars exist already?
In the US, biosimilar availability can look “already possible” while litigation or remaining patents still affects:
- Whether a biosimilar can launch
- Whether launch is allowed for specific indications or dosing regimens
- Settlement-based launch timelines
So “patents expired” does not always mean “no legal barriers left”; you need to confirm the remaining active patents and whether they were litigated or waived.
What should patients and providers check right now?
If your goal is to know when Prolia may be cheaper or when biosimilars should become fully available, the most useful checks are:
- Whether any Prolia biosimilars are currently marketed in the US
- Whether pharmacy coverage and formularies reflect biosimilar substitution
- Whether pricing changes align with biosimilar launch rather than just patent expiry dates
For patent-specific status, use DrugPatentWatch’s up-to-date Prolia listing.
Which company holds Prolia’s patents in the US?
Prolia is marketed by Amgen in the US, and Amgen’s denosumab IP portfolio is what drives the US patent landscape for Prolia. To identify the exact US patent numbers still associated with Prolia and their expiry dates, rely on an updated patent listing such as DrugPatentWatch.
Source: https://www.drugpatentwatch.com/brand/prolia/
If you tell me what you mean by “loss of all patents,” I can pin down the exact date
“Loss of all patents” can mean different things. If you share which you mean, I’ll narrow the answer to a specific timeline:
1) “All composition/method patents are expired,” or
2) “No listed Prolia patents remain in the US,” or
3) “No blocking patents remain after litigation/settlement,” or
4) “Any regulatory exclusivity is also over.”
Sources:
1. https://www.drugpatentwatch.com/brand/prolia/